LGGs with IDH mutation and 1p/19q codeletion are associated with the most favorable clinical outcome and possibly improved sensitivity to procarbazine, lomustine, and vincristine chemotherapy compared with noncodeleted neoplasms. The gene discussed is IDH2; the disease is neoplasm.